DELCATH SYSTEMS, INC. — Form 8-K
Filed November 9, 2026 · analyzed by the 8-K Agent
8-K
▲ Likely positive
significance 72/100
What the filing says
Delcath Systems reported Q3 2026 total revenue of $35.1M (up 71% YoY from $20.6M), with HEPZATO KIT revenue of $32.7M (up 69% YoY from $19.3M) and CHEMOSAT of $2.4M (up 85% YoY from $1.3M). Net income reached $7.0M vs. $0.8M YoY; adjusted EBITDA grew 117% to $11.5M. Management raised full-year 2026 revenue guidance to $115–117M (up from prior range), projecting ≥41% HEPZATO volume growth over 2025, with gross margins of 87–89% and positive adjusted EBITDA. Cash position strengthened to $104.3M with zero debt; company expanded to 33 active treatment centers and advanced Phase 2 DELUMA trial for breast cancer indication.
Why this rating
Strong execution; 71% Q3 revenue growth and raised FY guidance materially above baseline. At ~$420M market cap, $115–117M annual revenue is 27–28% of valuation—meaningful scale milestone. Early profitability and positive EBITDA inflection, plus pipeline expansion (cholangiocarcinoma IND planned early 2027) and clinical progress reduce execution risk. Strong balance sheet supports growth. Relative to company size, this represents real trajectory acceleration.
Tradability signal
SHORT
conviction 20/100 · expected -0.57% over 4 hrs
SHORT (fade the pop): stock already ran +12.8% on this news, and positive calls in this cell have historically given the pop back (-0.60% over 4 hrs, n=396). Reversion play, lower conviction by design. Exit plan: HARD stop 8% against entry — 1.4× this stock's measured hourly volatility, fixed, not trailing (trails test terribly on these names) — time exit 4 hrs. (Filing arrived outside market hours — evaluated at the next open with a live quote.)
Derived from this site's own measured outcomes + live price/liquidity at analysis time. An experiment, not investment advice.
Price action (we called it positive)
before filing · preread $16.50 ▼ 11.40% | at our read · unknown $18.62 | +10 min · unknown $19.16 ▲ 2.88% | +30 min · unknown $19.14 ▲ 2.78% | +1 hr · unknown $19.00 ▲ 2.04% | +4 hrs · unknown $19.13 ▲ 2.73% |
The stock had already moved +12.86% between hitting EDGAR and our read finishing — deltas above are measured from our read.
Quotes via Yahoo Finance at capture time; for filings arriving outside market hours the clock starts at the next open. Not investment advice. How accurate are our calls? →
See more from November 9, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.